drugset / Trial / NCT05196971
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of intranasal HS-10345 (84mg) compared with placebo in participants with treatment-resistant depression (TRD).
Timeline
- Start
- 2021-10-28
- Primary completion
- 2022-04-30
- Completion
- 2022-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10345 | Unknown | 84 mg | Intranasal |